Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
Clinical trial NCT00375219 · COMPLETED
Trial details
- NCT number
- NCT00375219
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2006-09-20
- Primary completion
- 2010-03-23
- Enrollment
- 103
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.